Trial watch: anticancer vaccination with dendritic cells

Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-speci...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Francisca Borges, Raquel S. Laureano, Isaure Vanmeerbeek, Jenny Sprooten, Octavie Demeulenaere, Jannes Govaerts, Lisa Kinget, Saurabh Saraswat, Benoit Beuselinck, Steven De Vleeschouwer, Paul Clement, Frederik De Smet, Rüdiger V. Sorg, Angeliki Datsi, Nathalie Vigneron, Stefan Naulaerts, Abhishek D. Garg
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Taylor & Francis Group 2024-12-01
سلاسل:	OncoImmunology
الموضوعات:	Antigen cross-presentation clinical trial DAMPs dendritic cells immune checkpoint blockers T cell priming
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/2162402X.2024.2412876
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!